$116.10
2.12%
Nasdaq, Apr 21, 07:44 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$118.61
-24.93 17.37% 1M
-70.94 37.43% 6M
-34.31 22.44% YTD
-73.55 38.28% 1Y
-93.93 44.19% 3Y
-223.94 65.37% 5Y
-267.74 69.30% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+3.32 2.88%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $17.36b
Enterprise Value $21.70b
P/E (TTM) P/E ratio 10.61
EV/FCF (TTM) EV/FCF 7.97
EV/Sales (TTM) EV/Sales 2.34
P/S ratio (TTM) P/S ratio 1.87
P/B ratio (TTM) P/B ratio 1.03
Revenue growth (TTM) Revenue growth -1.60%
Revenue (TTM) Revenue $9.27b
EBIT (operating result TTM) EBIT $2.08b
Free Cash Flow (TTM) Free Cash Flow $2.72b
Cash position $2.38b
EPS (TTM) EPS $11.18
P/E forward 9.28
P/S forward 1.89
EV/Sales forward 2.36
Short interest 2.58%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a Biogen forecast:

17x Buy
46%
20x Hold
54%

Analyst Opinions

37 Analysts have issued a Biogen forecast:

Buy
46%
Hold
54%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
9,267 9,267
2% 2%
100%
- Direct Costs 3,024 3,024
0% 0%
33%
6,243 6,243
2% 2%
67%
- Selling and Administrative Expenses 1,691 1,691
18% 18%
18%
- Research and Development Expense 1,755 1,755
21% 21%
19%
2,797 2,797
32% 32%
30%
- Depreciation and Amortization 713 713
44% 44%
8%
EBIT (Operating Income) EBIT 2,084 2,084
28% 28%
22%
Net Profit 1,632 1,632
41% 41%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Neutral
GlobeNewsWire
6 days ago
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4 * ) non-carriers or heterozygotes with confirmed amyloid pathology
Positive
Reuters
6 days ago
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Neutral
Investors Business Daily
11 days ago
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,605
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today